WELL Health Technologies (TSX: WELL) this morning announced yet another financing that is to be conducted by the firm. This go around, the company will be raising $70.0 million through a bought deal financing, lead by Eight Capital and Stifel GMP.
The bought deal financing will see a total of 10,372,000 common shares of the company sold at a price of $6.75 per share, with no warrant being offered in the financing. An over allotment option also exists, enabling the underwriters to sell an additional 15% of shares upon exercise for up to thirty days following the close of the financing. If exercised, this option would bring the total financing to $80.5 million.
Proceeds from the financing are to be used to fund future acquisitions, as well as the firms investment in digital healthcare. To this end, the company included a wide range of potential investments or acquisitions, including “tech-enabled” primary and specialty clinics, electronic medical record software, cybersecurity, virtual care platforms or other assets. Funds will also be used for working capital and general corporate purposes.
The financing is expected to close by October 22, 2020. It follows an announcement from just yesterday, wherein the firm released that it had closed a $23 million private placement financing at $4.77 per unit. Notably, the company utilized a different wire service than is typical to announce this mornings financing.
WELL Health last traded at $7.21 on the TSX.
Information for this briefing was found via Sedar and WELL Health Technologies Corp. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
